Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?
In June 2024, WHO released ‘Key updates to the treatment of drug-resistant tuberculosis: rapid communication’, after the preliminary publication of results from two clinical trials: ‘BEAT-Tuberculosis’ and ‘endTB’. All proposed regimens include clofazimine (Cfz). However, a recent paper has reported...
Saved in:
Main Authors: | E. Pontali, M. Raviglione |
---|---|
Format: | Article |
Language: | English |
Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-11-01
|
Series: | IJTLD Open |
Subjects: | |
Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000011/art00002 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TB drug susceptibility testing in high fluoroquinolone resistance settings
by: F. Saluzzo, et al.
Published: (2024-05-01) -
A survey of the effectiveness of centralized consilia in providing advice on drug-resistant TB
by: A. Vasquez, et al.
Published: (2024-07-01) -
The impact of the war in Ukraine on the prevalence of MDR/RR-TB in Poland
by: A. Nowinski, et al.
Published: (2025-01-01) -
The TB burden in East Java, Indonesia, post-COVID-19
by: S. Palupi, et al.
Published: (2024-08-01) -
Progress in programmatic management of drug-resistant TB, WHO Eastern Mediterranean Region, 2018-2023
by: K. Bennani, et al.
Published: (2024-09-01)